Scott Grossman
About Scott Grossman
Scott Grossman is the President of Grossman Pharma Consulting, LLC in Hopewell, New Jersey, with extensive experience in pharmaceutical research and development.
Grossman Pharma Consulting, LLC
Scott Grossman currently serves as the President of Grossman Pharma Consulting, LLC, based in Hopewell, New Jersey. He started this role in October 2011, leveraging his extensive experience in the pharmaceutical industry to guide organizations through the complexities of drug discovery and development. Earlier roles within the same company included VP and Scientific Director at the Biocon-BMS Research and Development Center in Bangalore, India from 2010 to 2011, and VP of Pharmaceutical Candidate Optimization from 2003 to 2010.
Career in the Pharmaceutical Industry
Throughout his career, Scott Grossman has held various significant positions within the pharmaceutical sector. He served as Executive Director of Metabolism and Pharmacokinetics at Bristol-Myers Squibb from 2001 to 2003. Before that, he was Director at DuPont Pharmaceuticals from 1998 to 2001 and held dual roles at Merck as Director of Biochemical and Investigative Toxicology and as a Scientist from 1987 to 1998. Additionally, he was a Staff Fellow at the National Institutes of Health from 1985 to 1987.
Educational Background in Pharmacology and Toxicology
Scott Grossman attained his Ph.D. in Pharmacology from the Medical University of South Carolina from 1981 to 1985. Also, he completed his M.S. in Environmental Toxicology and B.S. in Biochemistry at the University of Wisconsin-Madison, spanning the years 1974 to 1981. His comprehensive educational background laid a strong foundation for his extensive career in drug discovery and early development.
Broad Expertise in Drug Development
Scott Grossman brings a broad and integrated understanding of drug development. He has successfully taken over 100 molecules from discovery into development, demonstrating strong problem-solving skills in small molecule drug discovery and early development. His efforts have built and led large, world-class organizations within the industry, emphasizing his capability in guiding projects from the lead molecule stage to proof of concept.